Loading organizations...
§ Venture Capital · USA
Venture capital firm raising and managing funds to invest in psychedelic therapies and mental and behavioral health startups.
Key people at Iter Investments.
Iter Investments is a Florida-based venture capital firm focused on investing in psychedelic therapies and companies advancing mental and behavioral health. The firm's investment strategy involves sourcing, diligencing, and managing capital across the entire mental health value chain, supported by a diverse team comprising investors, legal professionals, scientists, physicians, and executives. Iter Investments successfully closed its inaugural fund at over $20 million in 2021, strategically deploying capital into the emerging psychedelic market. The firm also holds ownership of Nucleus Holdings, an entity designed to provide broader access to the alternative therapies ecosystem. This strategic positioning allows Iter Investments to engage with a wide range of opportunities within the sector. Iter Investments was founded in 2021 by Dustin Robinson and Robert Velarde.
Key people at Iter Investments.
Iter Investments has 3 tracked investments across 3 companies. The latest tracked deal is $30.0M Series A in Sensorium Therapeutics in October 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 1, 2022 | Sensorium Therapeutics | $30.0M Series A | Santé Ventures | Arboretum Ventures, CU Healthcare Innovation Fund, Ocama Partners, Palo Santo, Re.Mind Capital, Route 66 Ventures, Wpss |
| Feb 26, 2022 | Fluence | $3.0M Seed | Simeon Schnapper, NEO Kuma Ventures, Palo Santo | Matthew Emerman, Michael Cotton, Noah Levy, Baroda Ventures, Evolve Ventures, Foundation Ventures, LearnStart |
| Jun 1, 2021 | Psilera | $3.0M Seed | — | — |
Iter Investments is a venture capital firm dedicated to transforming mental and behavioral health by backing breakthrough companies in the alternative therapeutics ecosystem, with a strong focus on psychedelics. Its mission is to support innovative startups that are redefining how mental health conditions are treated—moving beyond traditional pharmaceuticals toward more holistic, science-backed, and often psychedelic-assisted modalities. The firm invests primarily at the seed and Series A stages, targeting early-stage companies in health tech, biotechnology, therapeutics, consumer health, wellness, and psychedelic-enabled mental health platforms.
By concentrating on the emerging psychedelic and alternative therapeutics industry, Iter Investments plays a catalytic role in a rapidly evolving startup ecosystem. It helps de-risk and scale companies that are tackling some of the most pressing global health challenges—depression, anxiety, addiction, and trauma—while also advancing the legitimacy and accessibility of psychedelic medicine. Through strategic capital allocation and deep domain expertise, Iter is shaping the next generation of mental health infrastructure, from clinical platforms and retreats to data, media, and investment tools that support the broader ecosystem.
---
Iter Investments emerged in the early 2020s as part of a broader wave of investor interest in psychedelic science and mental health innovation. Founded and based in Florida, the firm was built by a multidisciplinary team of builders, investors, scientists, physicians, clinicians, lawyers, and technologists who shared a conviction: that the future of mental and behavioral health lies in alternative, often psychedelic-based, therapeutic models. The name “Iter” reflects this vision—derived from the Latin word for “pathway” or “journey,” and also referencing the cerebral aqueduct in the brain, symbolizing the passage between old and new paradigms in mental healthcare.
From the outset, Iter positioned itself not just as a capital provider but as a builder within the psychedelic ecosystem. Rather than passively investing, the team actively shaped infrastructure by launching Nucleus Holding, a holding company that incubates key ecosystem assets like Psychedelic Invest (a leading media and investment intelligence platform) and Neuly (a comprehensive psychedelic data and insights database). This builder mentality, combined with deep clinical and operational expertise, allowed Iter to move quickly in a nascent, complex, and highly regulated space, establishing itself as a trusted partner for founders pioneering the future of mental health.
---
Deep Ecosystem Integration- Iter doesn’t just invest in psychedelics—it helps build the ecosystem. Through Nucleus Holding, it owns and operates foundational assets like the leading psychedelic media platform and the first Psychedelic Index, giving it unmatched visibility into market trends, valuations, and emerging opportunities.
Domain Expertise Across the Value Chain- The team combines scientific, clinical, legal, and technological expertise, enabling rigorous diligence in a highly regulated field where understanding pharmacology, regulatory pathways, and clinical trial design is critical.
Builder-First, Operator-Led Approach- Many partners are former founders, operators, or clinicians, so they bring hands-on experience in scaling health tech and biotech companies.
Strategic Focus on Psychedelic & Alternative Therapeutics- While many funds dabble in psychedelics, Iter is one of the few with a concentrated, thesis-driven focus on the entire alternative therapeutics stack—from drug development and retreats to digital therapeutics, community platforms, and data infrastructure.
Early-Stage Edge with Follow-On Capacity- Active at seed and Series A, Iter often gets in at the earliest stages, giving it significant ownership and influence.
---
Iter Investments sits at the intersection of three powerful trends: the mental health crisis, the resurgence of psychedelic science, and the digitization of behavioral health. Globally, demand for mental health solutions is surging, yet traditional treatments remain inadequate for millions. At the same time, clinical research has validated the therapeutic potential of psychedelics like psilocybin, MDMA, and ketamine, creating a new frontier for innovation. Iter is positioned at the epicenter of this shift, backing companies that are building the tools, platforms, and experiences that will define the next era of mental healthcare.
The firm is also helping to professionalize and legitimize the psychedelic industry. By funding science-backed retreats (like Beckley Retreats), clinical-grade PsyTech platforms, and robust data and media infrastructure, Iter is reducing noise and increasing credibility in a space that has historically struggled with hype and regulatory uncertainty. As regulators in the U.S. and Europe move toward approving psychedelic-assisted therapies, Iter’s portfolio companies are well-positioned to become key players in the commercial rollout.
Moreover, Iter’s work reflects a broader trend in venture capital: the rise of “ecosystem investors” who don’t just fund startups but actively build the infrastructure that enables an entire industry to scale. In this sense, Iter is less like a traditional VC and more like a strategic architect of the psychedelic and alternative therapeutics landscape.
---
Iter Investments is poised to become one of the defining venture firms in the alternative therapeutics space. As psychedelic-assisted therapies move closer to mainstream adoption, the companies and infrastructure Iter has backed—from clinical platforms and retreats to data and media—will become increasingly valuable. The firm’s early, concentrated bet on psychedelics, combined with its builder mentality, gives it a structural advantage over generalist funds that entered the space later.
Looking ahead, Iter is likely to deepen its focus on the full mental health value chain: from drug development and clinical delivery to digital therapeutics, community, and long-term wellness. It may also expand its fund strategy to include later-stage or sector-specific vehicles as the ecosystem matures. The success of its portfolio companies, especially those at the intersection of psychedelics and technology, could influence how investors, regulators, and healthcare systems think about mental health innovation.
In a world where mental health is no longer a side issue but a central challenge of our time, Iter Investments is not just funding startups—it’s helping to forge the pathway to a new paradigm of healing.
